一种用于检测肝硬化的唾液生物标志物组合。
A salivary biomarker panel to detect liver cirrhosis.
作者信息
Trevisan França de Lima Lucas, Crawford Darrell H G, Broszczak Daniel A, Zhang Xi, Bridle R Kim, Punyadeera Chamindie
机构信息
The School of Environment and Science, Griffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, QLD, Australia.
Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, QLD, Australia.
出版信息
iScience. 2023 Jun 5;26(7):107015. doi: 10.1016/j.isci.2023.107015. eCollection 2023 Jul 21.
Limited access to diagnostic tests for liver fibrosis remains one of the main reasons for late diagnosis, especially in rural and remote communities. Saliva diagnostics is accessible with excellent patient compliance. The aim of this study was to develop a saliva-based diagnostic tool for liver fibrosis/cirrhosis. Salivary concentrations of hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1), and α-2-macroglobulin (A2MG) were significantly increased (p < 0.05) in patients with liver fibrosis/cirrhosis. By combining these biomarkers, we developed the Saliva Liver Fibrosis (SALF) score, which identified patients with liver cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.970 and 0.920 in a discovery and validation cohorts, respectively. The SALF score had a performance that was similar to that of the current Fibrosis-4 (AUROC:0.740) and Hepascore (AUROC:0.979). We demonstrated the clinical utility of saliva to diagnose liver fibrosis/cirrhosis with a potential to improve the screening for cirrhosis in asymptomatic populations.
获得肝纤维化诊断检测的机会有限仍然是晚期诊断的主要原因之一，尤其是在农村和偏远社区。唾液诊断易于进行，患者依从性良好。本研究的目的是开发一种基于唾液的肝纤维化/肝硬化诊断工具。肝纤维化/肝硬化患者唾液中的透明质酸（HA）、金属蛋白酶组织抑制因子-1（TIMP-1）和α-2-巨球蛋白（A2MG）浓度显著升高（p<0.05）。通过组合这些生物标志物，我们开发了唾液肝纤维化（SALF）评分，在发现队列和验证队列中，该评分分别以0.970和0.920的受试者工作特征曲线下面积（AUROC）识别出肝硬化患者。SALF评分的表现与目前的Fibrosis-4（AUROC：0.740）和Hepascore（AUROC：0.979）相似。我们证明了唾液在诊断肝纤维化/肝硬化方面的临床实用性，有可能改善无症状人群中肝硬化的筛查。
Zotero 插件